The Generium-next company (a resident of the Technopolis Moscow SEZ) has launched a workshop for the production of drugs for the treatment of bronchial asthma, cardiovascular, rare and hereditary diseases. This was told by the Deputy Mayor of Moscow on economic policy and property and land relations Vladimir Efimov, the press service of DIiPP reported.
"Generium-next Company" received the status of a resident of the special economic zone of Moscow last year. The company rented a room with an area of about 500 m2 at the Alabushevo site, where it placed a workshop for the secondary packaging and production of drugs for the treatment of complications of bronchial asthma and rare, so-called orphan diseases, including Gaucher's disease and cystic fibrosis. The first batches of products have already been sent to pharmaceutical institutions. It is planned that the workshop will produce more than 150 thousand units of products annually and will reach full capacity by the end of 2024. Today, the company's customers are dozens of Moscow public and private medical institutions," he said Vladimir Efimov.
The company plans to build its own plant at the Alabushevo site by 2024 and invest almost 5 billion rubles in it, the deputy mayor added.
Generium-next implements a full cycle of production of biotechnological preparations – from the creation of a molecule to the beginning of industrial production. She conducts research on individual drugs in collaboration with leading biotech companies and research institutes from around the world. The company is a leader in the orphan segment of the Russian pharmaceutical market.
Technopolis Moscow SEZ is a territory with a special legal status, where a preferential business regime for investors operates. The area of five sites ("Printers", "Alabushevo", "Micron", "MIET", "Angstrom"), where high-tech enterprises of the SEZ are located, exceeds 223 hectares. The total area of the production buildings is 550 thousand m2.
